Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations — Stella
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(23 sites)
France
CLCC Jean Perrin, Clermont-Ferrand
CLCC Léon Bérard, Lyon
Institut Mutualiste Montsouris, Paris
IUCT, Toulouse
Institut Gustave Roussy, Villejuif
Italy
IRCCS San Raffaele Hospital and Scientific Institute, Milan
A.O. Ordine Mauriziano, Ospedale Umberto I, Turi
Ospedale Molinette, Turin
Spain
Hospital Clínic De Barcelona, Barcelona, Catalonia
Hospital De Sabadell (Parc Taulí), Barcelona, Catalonia
Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia
Hospital Universitario Lucus Augusti, Lugo, Galicia
ICO l' Hospitalet, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario de Toledo, Toledo
Fundación Instituto Valenciano De Oncología, Valencia
Hospital Clínico Universitario De Valladolid, Valladolid
Hospital Universitario Miguel Servet, Zaragoza
United Kingdom
University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster
The Royal Marsden NHS Foundation Trust, London
Barts Health NHS Trust, London
Charing Cross Hospital, London
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield